Pharma BD Deal Intelligence
On January 8, 2024, Merck announced an agreement to acquire Harpoon Therapeutics for $23.00 per share in cash, an approximate total equity value of $680 million, further diversifying its oncology pipeline. Harpoon is a clinical-stage immunotherapy company developing T-cell engagers. Its lead candidate, gocatamig (MK-6070, formerly HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand expressed at high levels in small cell lung cancer and neuroendocrine tumors. The transaction completed in March 2024; Merck subsequently reported the acquisition at $765 million together with $56 million of transaction costs, reflecting final consideration and accounting treatment. Strategically the deal is a bolt-on addressing Merck's need to build revenue ahead of Keytruda loss of exclusivity.
Assessment window: 5yr post-close.
Note: this deal's 5-year assessment window closes Mar 2029; the outcome grade above is a projected assessment, not yet finalized.
Small cell lung cancer is a high-grade neuroendocrine carcinoma characterised by rapid growth, early metastasis and initial chemosensitivity followed by near-universal relapse. Incidence has declined with falling smoking prevalence, but survival outcomes have remained largely stagnant.
DLL3 is the dominant SCLC surface target. Tarlatamab (DLL3xCD3 bispecific T-cell engager) established clinical proof of concept and set the competitive bar; other entrants include DLL3-directed T-cell engagers and antibody-drug conjugates. Standard of care remains platinum-etoposide with a PD-L1 inhibitor (atezolizumab or durvalumab) in the first line, with lurbinectedin and topotecan in later lines.
Neuroendocrine tumors are a heterogeneous group of malignancies arising from neuroendocrine cells across the gastrointestinal tract, pancreas and lung. High-grade neuroendocrine carcinomas share DLL3 expression with small cell lung cancer, providing a biologic rationale for extending DLL3-directed therapy beyond SCLC.
DLL3 is an inhibitory canonical Notch ligand aberrantly expressed on the surface of high-grade neuroendocrine tumors while largely absent from normal tissue, making it a favourable T-cell engager target in this setting.
Merck announced an agreement to acquire Harpoon Therapeutics for $23.00 per share in cash, an approximate equity value of $680 million, to add the DLL3-targeted T-cell engager MK-6070.
Merck completed the acquisition of Harpoon Therapeutics in March 2024, later recording the transaction at $765 million with $56 million of transaction costs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck Sharp & Dohme LLC / Harpoon Therapeutics, Inc. (this deal) | 2024 | $680M | 65 |
| Nuvation Bio Inc. / AnHeart Therapeutics, Ltd. | 2024 | — | 100 |
| Novo Holdings A/S / Catalent (manufacturing sites) | 2024 | $11.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Johnson & Johnson / Shockwave Medical | 2024 | $13.1B | 76 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
← Browse all deals · How we score deals
More: 2024 deals